Cure8 news brief
The FDA approval expands an approved biologic option (ustekinumab/Stelara) to children aged two and older with moderately to severely active ulcerative colitis, giving families and clinicians another treatment choice. It also follows a recent pediatric approval of the same drug for Crohn’s disease.
Pediatric patients with moderate-to-severe UC and their parents/caregivers; pediatric and adult gastroenterologists managing IBD; patients exploring biologic therapies.
The FDA’s decision covers use of Stelara (ustekinumab) injection for moderately to severely active ulcerative colitis in pediatric patients aged two years and above. The article notes this approval comes after an earlier pediatric approval of Stelara for Crohn’s disease.
Stelara is the brand name for ustekinumab, an interleukin-12/23 inhibitor used as a biologic therapy for inflammatory bowel disease. This news is a regulatory approval announcement; it does not present new clinical trial data or prescribing details in the supplied text.
If you or a child in your care is considering biologic treatment for UC, discuss with your treating clinician whether ustekinumab is appropriate, how it is given, and how it fits with other treatment options and monitoring.
This is a regulatory approval announcement; the supplied text does not provide trial data, dosing, safety, or coverage details. Consult the FDA label and your care team for full prescribing information.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.
This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...
A newly FDA-approved biologic (guselkumab/Tremfya) offers another treatment option for adults with moderate to severe Crohn’s disease, including both IV and SC induction choices. This could matter for patients who have...
